Latest Updates
-
Ralph Lauren Showcases ‘Jhumkas’ At Paris Fashion Week, Rekindling Debate On Credit For Indian Craft -
Viral Video: Pakistani Family Celebrates India’s T20 World Cup Victory With Cake, Sings Indian National Anthem -
Who Is Aditi Hundia? Viral Video Shows Ishan Kishan Celebrating India’s T20 World Cup Win With Girlfriend -
India Seal Historic T20 World Cup Win: Samson Tournament Star, Bumrah Match Hero, Dhoni Posts Special Message -
Horoscope for Today March 09, 2026 - Small Steps, Big Progress -
International Women’s Day 2026: 7 Powerful Ayurvedic Foods Every Woman Should Start Adding To Her Daily Diet -
What If WiFi, GPS Or Dishwashers Didn’t Exist? This Instagram Reel Credits Women Behind Everyday Inventions -
Women’s Day 2026: Why Creating Relaxation Spaces At Home Matters For Women Balancing Multiple Roles -
Women’s Day 2026 Binge Watch: 10 Movies That Celebrate Women Who Challenge Norms And Rewrite Their Stories -
Women’s Day 2026 Exclusive: Saumya Tandon On Dhurandhar Success, ‘Actors Must Break The Boxes’
DCGI Approves India's First qHPV Vaccine Against Cervical Cancer
Update: As per recent news reports, the DCGI subject expert committee has approved Serum Institute's indigenously created qHPV vaccination for cervical cancer. It will be India's first indigenous cervical cancer vaccine.

Serum Institute of India (SII) has applied to the country's drug regulator seeking market authorisation to manufacture indigenously developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer, official sources said on Wednesday, June 8.
The Pune-based firm has applied for market authorisation after completing the phase 2/3 clinical trial with support of the Department of Biotechnology to ensure its early availability in the country, they said.
In the application to the Drugs Controller General of India (DCGI), Prakash Kumar Singh, director (government and regulatory affairs) at SII, said the vaccine CERVAVAC has demonstrated a robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.
The SII is also learnt to have made a presentation before the working group of HPV under the chairmanship of Dr NK Arora constituted separately by the NTAGI to review the data and usefulness of this vaccine on Wednesday, the sources said.

In the application, Singh mentioned that every year lakhs of women are diagnosed with cervical cancer as well as few other cancers and death ratio is also very high.
Cervical cancer in India ranks as the second-most frequent cancer among women between 15 and 44 years of age.
"Also, it is noteworthy that presently, our country is fully dependent on foreign manufacturers for the HPV vaccine. In line with the philosophy of our group & under the leadership of our CEO, Dr Adar C Poonawalla, it has always been our endeavour to make available high quality 'Made in India' vaccines at an affordable price for people of our country and the world at large," Singh said in the application.
"Like many other indigenous life-saving vaccines, we are committed to making our country 'ATMANIRBHAR' for India's first indigenous life-saving qHPV vaccine also. This will fulfill the dream of our Hon'ble Prime Minister Narendra Modi 'VOCAL FOR LOCAL' and 'MAKING IN INDIA FOR THE WORLD' and will ensure the prevention of cancers caused by Human Papillomavirus (Type 6, 11, 16 & 18) vaccine recombinant," Singh is learnt to have said in the application.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications











